
    
      This will be a single centre, bioequivalence, open-label, randomized, single-dose, 3-period,
      3-sequence, reference replicated, crossover study. 36 healthy adult males or non-childbearing
      potential females, ≥18 and ≤65 years of age, smoker and/or non-smoker.
    
  